How concerning is Moderna's latest bad news? Let's first look at why investors were so unhappy with Moderna's business update. The company generated product sales of between $3 billion and $3.1 ...

Since its founding in 2010, Moderna has aimed to redefine medicine by pioneering messenger RNA (abbreviated mRNA) technology. mRNA is a type of single-stranded RNA involved in protein synthesis.

Moderna, a leader in mRNA medicine, developed one of the earliest COVID-19 vaccines, with Spikevax being its first commercial product. The company's mRNA platform enables the development of ...

Northwestern University has filed a patent infringement lawsuit against Moderna, Inc. (NASDAQ:MRNA), alleging the pharmaceutical company used the university’s lipid nanoparticle (LNP) technology ...

Moderna ...

Moderna said Monday that its combination vaccine against flu and COVID-19 drew a greater immune response in late-stage study results than two comparable vaccines on the market. The company's ...

摘要：2026 年1月5日，Moderna 宣布就旗下 mRNA 流感疫苗 mRNA-1010，向美国、欧洲、加拿大、澳大利亚四国监管机构提交上市申请，该疫苗针对 50 岁及以上人群，有望成为公司扭转业绩颓势的关键。其基于 mRNA ...

Moderna's post-pandemic vaccine demand is weak, with mRESVIA unlikely to gain significant RSV market share due to commoditization and entrenched competitors. Financials remain strained: high costs, ...

Moderna, Inc. (NASDAQ:MRNA) 周一宣布已向其股东发布一封信函。该公司在美国证券交易委员会的FD披露条例下公开了这一信息。目前Moderna股价为$30.86，尽管面临重大挑战，但年初至今仍实现了4.65%的适度增长。

CAMBRIDGE, MA / ACCESS Newswire / September 16, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced positive preliminary immunogenicity data for the 2025-2026 formula of Spikevax®, which targets the LP ...

全球领先的 AI 研究机构 OpenAI 近日宣布了一项关键人事任命，聘请 Brice Challamel 担任 AI 策略与采用负责人。这一职位的核心使命是协助全球大型企业跨越 AI 的“实验阶段”，实现大规模且负责任的商业化落地。

Moderna, Inc. (NASDAQ:MRNA) shares are getting hit because of a bad earnings report. The Street didn't like the numbers. The shares have broken a support level and may form a new downtrend. This is ...